Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
407 Leser
Artikel bewerten:
(2)

Manipal Hospitals launches the first Radixact System with Synchrony technology in India

BENGALURU, India, Aug. 27, 2021 /PRNewswire/ -- Manipal Hospitals, India's second largest multi-speciality hospital chain, has launched the first-of-its-kind advanced Radixact System with the Synchrony Automatic, Real-time Motion Synchronization Technology, for the precise treatment of cancer patients. Manipal Hospitals' has obtained the requisite license from AERB for Radixact X9 Tomotherapy with Synchrony tumor tracking technology, which is the first machine with this feature in India. India is the first developing nation in the world to avail the new Radixact System.

L-R- Patient's son (Hitesh Prabhu); Dr H Sudarshan Ballal, Chairman, MHEPL, Dr Vadhiraja BM, HOD & Consultant, Radiotherapy, & Dr Manish Rai, Hospital Director, Manipal Hospitals launched Radixact with Synchrony Technology

The Radixact System, with its new generation of Tomotherapy with Synchrony technology serves cancer patient needs, by far superior clinical results in head & neck, breast, GI & prostate cancers, which consolidate for more than 85% of occurrence. The System delivers 360 degree rotational delivery for the whole body and CT based daily IGRT treatment with Iterative reconstruction. The combined technologies enable the delivery of radiation using a variety of methods - from image-guided intensity-modulated radiation therapy (IG-IMRT) to stereotactic body radiation therapy (SBRT) - to treat almost any tumor, even those that move with breathing, precision, accuracy and unprecedented flexibility.

Dr. Vadhiraja B M, HOD & Consultant - Radiotherapy, Manipal Hospitals, Old Airport Road, stated, "Manipal Hospitals has always emphasized on providing the patients with the best universally available treatment and care. The Synchrony technology is expected to revolutionise cancer treatment by significantly lowering the discomfort undergone by cancer patients. Synchrony for the Radixact System will provide clinicians with the technology they need to effectively and efficiently treat cancer patients requiring radiation therapy, in whom the tumor moves while breathing."

The advantages of Synchrony technology include:

  1. It enables clinicians to administer highly precise radiation to the tumor region which moves with natural breathing, i.e cancer in lung (primary or metastatic), liver, pancreas & prostate
  2. Provides comfort of natural breathing by the patient during radiation and reduces overall treatment time compared to the current radiation treatment technologies for cancer
  3. Minimizes the damage inflicted on healthy tissues surrounding the tumors, which are exposed to high-dose radiation, with minimal discomfort to the patient
  4. Tracks, detects the tumor and corrects its positions all within an adaptive time of 0.3 seconds and precisely administers dosage, with minimal invasion or discomfort to the patient.

Manipal Hospitals constantly upgrades the technology to provide the best treatment for every cancer patient.

Contact:
Archana Jain
archana@conceptindia.com
+91-9845541244

Photo: https://mma.prnewswire.com/media/1603301/Manipal_Hospitals_Radixact_System.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.